Pregnant women with metabolic syndrome components are still considered at high risk despite all the scientific
efforts that have occurred along the years to promote quality more and more. Yet, the control of this is lower
than desired. Thus, perinatal adverse effects (malformations, neonatal, neonatal hypoglycemia, and neonatal
macrosomia jaundice) continue to increase and this increase is directly proportional to the values and Components
numbers of MS presented